Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | FNTA | P49354 | 5/20 | 0.51 |
| ▸ | FNTB | P49356 | 5/20 | 0.51 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630397 | 0.90 | MMP2 (0.59) | MMP2 | |
| SCHEMBL30179375 | 0.90 | MMP2 (0.58) | MMP2LTA4H | |
| SCHEMBL29630539 | 0.89 | MMP2 (0.53) | MMP2FNTAFNTBPGGT1BLTA4H | |
| SCHEMBL29592318 | 0.88 | FNTA (0.56) | FNTAFNTBPGGT1BLTA4H | |
| SCHEMBL29630651 | 0.88 | FNTA (0.56) | FNTAFNTBPGGT1BLTA4H | |
| SCHEMBL30575182 | 0.88 | FNTA (0.43) | BACE1FNTAFNTBPGGT1B | |
| SCHEMBL29591888 | 0.87 | LTA4H (0.53) | FNTAFNTBPGGT1BLTA4H | |
| SCHEMBL31721016 | 0.87 | FNTA (0.55) | FNTAFNTBPGGT1BLTA4H | |
| SCHEMBL31501129 | 0.86 | LTA4H (0.51) | BACE1FNTAFNTBPGGT1BLTA4H | |
| SCHEMBL29630392 | 0.86 | LTA4H (0.54) | FNTAFNTBPGGT1BLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | BACE1 530/4885MMP2 1901/4885FNTA 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.